Sanofi, GSK kick off Phase III trial for COVID-19 shot

France's Sanofi and Britain's GlaxoSmithKline launched a late-stage human trial for a recombinant COVID-19 vaccine candidate on Thursday which they hope to get approved by the end of 2021. The study initiated by Sanofi and GSK is one of the first late stage trials that combines tests for boosters and variants, as drugmakers adapt their strategies to deal with an evolving coronavirus.